248 related articles for article (PubMed ID: 33818884)
1. Neuroblastoma.
Chung C; Boterberg T; Lucas J; Panoff J; Valteau-Couanet D; Hero B; Bagatell R; Hill-Kayser CE
Pediatr Blood Cancer; 2021 May; 68 Suppl 2(Suppl 2):e28473. PubMed ID: 33818884
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
5. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.
Marcus KJ; Shamberger R; Litman H; von Allmen D; Grupp SA; Nancarrow CM; Goldwein J; Grier HE; Diller L
J Pediatr Hematol Oncol; 2003 Dec; 25(12):934-40. PubMed ID: 14663275
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
Mazloom A; Louis CU; Nuchtern J; Kim E; Russell H; Allen-Rhoades W; Krance R; Paulino AC
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):858-62. PubMed ID: 25245583
[TBL] [Abstract][Full Text] [Related]
7. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
8. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
Kreissman SG; Seeger RC; Matthay KK; London WB; Sposto R; Grupp SA; Haas-Kogan DA; Laquaglia MP; Yu AL; Diller L; Buxton A; Park JR; Cohn SL; Maris JM; Reynolds CP; Villablanca JG
Lancet Oncol; 2013 Sep; 14(10):999-1008. PubMed ID: 23890779
[TBL] [Abstract][Full Text] [Related]
9. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Berthold F; Boos J; Burdach S; Erttmann R; Henze G; Hermann J; Klingebiel T; Kremens B; Schilling FH; Schrappe M; Simon T; Hero B
Lancet Oncol; 2005 Sep; 6(9):649-58. PubMed ID: 16129365
[TBL] [Abstract][Full Text] [Related]
10. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
11. Management of Neuroblastoma: ICMR Consensus Document.
Bansal D; Totadri S; Chinnaswamy G; Agarwala S; Vora T; Arora B; Prasad M; Kapoor G; Radhakrishnan V; Laskar S; Kaur T; Rath GK; Bakhshi S
Indian J Pediatr; 2017 Jun; 84(6):446-455. PubMed ID: 28367616
[TBL] [Abstract][Full Text] [Related]
12. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
13. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results.
Matthay KK; O'Leary MC; Ramsay NK; Villablanca J; Reynolds CP; Atkinson JB; Haase GM; Stram DO; Seeger RC
Eur J Cancer; 1995; 31A(4):572-5. PubMed ID: 7576971
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.
Matthay KK; Seeger RC; Reynolds CP; Stram DO; O'Leary MC; Harris RE; Selch M; Atkinson JB; Haase GM; Ramsay NK
J Clin Oncol; 1994 Nov; 12(11):2382-9. PubMed ID: 7964954
[TBL] [Abstract][Full Text] [Related]
15. [Long-term effect of high dose chemotherapy combined with stem cell transplantation on stage IV neuroblastoma in children].
Tang SQ; Huang DS; Wang JW; Feng C; Yang G
Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):93-6. PubMed ID: 16613697
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2010 May; (5):CD006301. PubMed ID: 20464740
[TBL] [Abstract][Full Text] [Related]
17. Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome.
Usmani N; Deyell RJ; Portwine C; Rafael MS; Moorehead PC; Shammas A; Vali R; Farfan M; Vanniyasingam T; Morgenstern DA; Irwin MS
Pediatr Blood Cancer; 2021 Dec; 68(12):e29289. PubMed ID: 34411405
[TBL] [Abstract][Full Text] [Related]
18. Ten challenges in the management of neuroblastoma.
Gains J; Mandeville H; Cork N; Brock P; Gaze M
Future Oncol; 2012 Jul; 8(7):839-58. PubMed ID: 22830404
[TBL] [Abstract][Full Text] [Related]
19. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.
Matthay KK; Reynolds CP; Seeger RC; Shimada H; Adkins ES; Haas-Kogan D; Gerbing RB; London WB; Villablanca JG
J Clin Oncol; 2009 Mar; 27(7):1007-13. PubMed ID: 19171716
[TBL] [Abstract][Full Text] [Related]
20. Relapse in the skull after myeloablative therapy for high-risk neuroblastoma.
Sangthawan D; DesRosiers PM; Randall ME; Robertson K; Goebel S; Fallon R
Pediatr Hematol Oncol; 2003; 20(1):23-30. PubMed ID: 12687750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
